Feldan Therapeutics

4975 Rideau Street
Suite 100
Quebec City
Quebec
G2E 5H5
Canada

Tel: 418-872-7277
Fax: 418-872-7007

About Feldan Therapeutics

Feldan Therapeutics has developed a peptide-based technology platform, the Feldan Shuttle, for direct delivery of proteins inside cells. The platform has been successfully used on several cell types (including human primary cells which are the center of most cell therapies) allowing the delivery of nucleases, transcription factors and antibodies. The Shuttle can overcome delivery obstacles in the context of therapeutic use by providing a safe and efficient approach that alleviates manipulation complexity and that is associated with low regulatory burden. Feldan Therapeutics' mission is to develop regenerative medicine therapeutic applications based on the Feldan Shuttle platform. Feldan Therapeutics has generated a pipeline of clinical applications taking advantage of the unique characteristics of the Shuttle.
YEAR FOUNDED:
2007
LEADERSHIP:
Founder and CEO: Francois-Thomas Michaud
JOBS:
Please click here for Feldan Therapeutics job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW FELDAN:
Tweets by Feldan

8 articles about Feldan Therapeutics

Feldan Therapeutics Secures $16.5m Series B to Bring Lead Asset to Clinical Development

6/13/2023

Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment.
Feldan Therapeutics Awarded Funding by Cystic Fibrosis Foundation

1/18/2022

Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced it was awarded funding by the Cystic Fibrosis Foundation to pursue the development of the Feldan Shuttle technology as a pulmonary delivery agent for cystic fibrosis.
Feldan Therapeutics Announces Additional Investment in Series A

11/27/2018

Feldan Therapeutics (hereafter "Feldan"), a preclinical biotechnology company specialized in the intracellular delivery of therapeutic proteins and peptides, has announced an investment of $1.3 million by Asahi Kasei Corporate Venture Capital (hereafter "AKCVC").
University of Iowa and Feldan Therapeutics awarded grant by the National Institutes of Health

10/12/2018

David Guay, Research Director of Feldan Therapeutics (hereafter "Feldan") announced that his collaborator, Dr. Paul McCray from the University of Iowa Carver College of Medicine, was awarded a $2 million grant
Feldan Therapeutics Raises $12.5 Million in Series A Financing Round

9/19/2018

Feldan Therapeutics has announced the closing of a $12.5 million Series A financing round led by GC
Feldan Therapeutics awarded US Patent for the second generation of its Feldan Shuttle platform

5/29/2018

Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform.
Feldan Therapeutics and Green Cross LabCell Announce Start of Joint Collaboration

1/15/2018

Green Cross LabCell today announced a joint research collaboration to develop low immunogenicity, high-performance natural killer anticancer treatment.
Feldan Therapeutics Announces Issuance Of First Patent For Its Peptide-Based Protein Delivery Technology, The Feldan Shuttle

8/23/2017